51
|
Lévesque H. [Acquired haemophilia: From registers' data to therapeutic recommendations]. Rev Med Interne 2012; 34:1-3. [PMID: 22998977 DOI: 10.1016/j.revmed.2012.08.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Accepted: 08/08/2012] [Indexed: 11/17/2022]
|
52
|
Tengborn L, Baudo F, Huth-Kühne A, Knoebl P, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119:1529-37. [DOI: 10.1111/j.1471-0528.2012.03469.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
53
|
Wechsler B, Canuel C, Geffray L, Hanslik T, Kettaneh A, Pavic M, Vignes S, Lévesque H, Pouchot J. Communications orales à l’honneur présentées au cours du 64e congrès de la Société nationale française de médecine interne (Paris, 14–16 décembre 2011). Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
54
|
Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10:622-31. [PMID: 22321904 DOI: 10.1111/j.1538-7836.2012.04654.x] [Citation(s) in RCA: 322] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. OBJECTIVES The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. RESULTS Five hundred and one (266 male, 235 female) patients from 117 centers and 13 European countries were included in the registry between 2003 and 2008. In 467 cases, hemostasis investigations and AHA diagnosis were triggered by a bleeding event. At diagnosis, patients were a median of 73.9 years. AHA was idiopathic in 51.9%; malignancy or autoimmune diseases were associated with 11.8% and 11.6% of cases. Fifty-seven per cent of the non-pregnancy-related cases were male. Four hundred and seventy-four bleeding episodes were reported at presentation, and hemostatic therapy initiated in 70.5% of patients. Delayed diagnosis significantly impacted treatment initiation in 33.5%. Four hundred and seventy-seven patients underwent immunosuppression, and 72.6% achieved complete remission. CONCLUSIONS Representing the largest collection of consecutive AHA cases to date, EACH2 facilitates the analysis of a variety of open questions in AHA.
Collapse
|
55
|
Dumesnil A, Bégarin L, Farès J, Benhamou Y, Cailleux-Talbot N, Marie I, Lévesque H. Une opacité pulmonaire unilatérale. Rev Med Interne 2012; 33:229-30. [DOI: 10.1016/j.revmed.2011.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Accepted: 03/11/2011] [Indexed: 10/28/2022]
|
56
|
Chauffrey L, Chamouni P, Bégarin L, Benhamou Y, Cailleux N, Borg JY, Callat MP, Schlegel N, Lévesque H. [MYH9 syndrome and auto-immune haemolytic anaemia: an unrelated association?]. Rev Med Interne 2012; 33:99-102. [PMID: 22217922 DOI: 10.1016/j.revmed.2011.11.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2011] [Accepted: 11/28/2011] [Indexed: 12/01/2022]
Abstract
INTRODUCTION The MYH9 syndrome is a group of rare autosomal dominant platelet disorders associating in most of the cases a macrothrombocytopenia and characteristic leukocyte inclusions. Clinical features may include renal, visual, or hearing impairment. The bleeding tendency is usually moderate. CASE REPORT We report a 28-year-old-man, with an auto-immune haemolytic anaemia associated with a MYH9 syndrome. CONCLUSION To our knowledge, this is the first report of such an association.
Collapse
|
57
|
Girszyn N, Fares J, Proust F, Héron F, Marie I, Lévesque H, Kaminsky P. Le berger et la blanche ingénue. Rev Med Interne 2011; 32:770-2. [DOI: 10.1016/j.revmed.2011.07.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Accepted: 07/13/2011] [Indexed: 10/17/2022]
|
58
|
Lévesque H. Post-internat et médecine interne : vers une réforme du troisième cycle médical des études médicales indispensable. Rev Med Interne 2011; 32:655-7. [DOI: 10.1016/j.revmed.2011.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2011] [Accepted: 08/09/2011] [Indexed: 10/17/2022]
|
59
|
de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C. Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study. Arthritis Care Res (Hoboken) 2011; 63:1188-94. [DOI: 10.1002/acr.20504] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
60
|
Belizna C, Loufrani L, Subra JF, Godin M, Jolly P, Vitecocq O, Faller B, Ghali A, Tron F, Hamidou M, Henrion D, Lévesque H, Ifrah N. A 5-year prospective follow-up study in essential cryofibrinogenemia patients. Autoimmun Rev 2011; 10:559-62. [PMID: 21549859 DOI: 10.1016/j.autrev.2011.04.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2011] [Accepted: 04/14/2011] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Cryofibrinogenemia may be essential, or secondary to diseases such as neoplasia, infection, thrombosis, and collagen vascular diseases. In a previous study, we reported the occurrence of neoplasia in some essential cryofibrinogenemia patients after a short period of follow-up. PURPOSE We performed a prospective multi-center 5-year follow-up study in essential cryofibrinogenemia patients (2005-2009). RESULTS 23 patients with essential cryofibrinogenemia were included, mean age 59 years (range: 33-79), 14 males. After a mean follow-up period of 24 months, 11/23 (47%) of cases that were initially diagnosed as essential cryofibrinogenemia were found to have an underlying lymphoma (6 T lymphoma and 5 B lymphoma). CONCLUSION This prospective study suggests that some cases of cryofibrinogenemia that are initially considered as essential, may have underlying lymphoma. Thus, we further suggest that regular follow-up should be performed in patients with essential cryofibrinogenemia.
Collapse
|
61
|
Josse S, Benhamou Y, Girault C, Lecam-Duchez V, Provost D, Verspyck E, Piquenot JM, Lévesque H, Queyrel V. Plaquettes-blues du post-partum. Rev Med Interne 2011; 32:255-60. [DOI: 10.1016/j.revmed.2010.12.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2010] [Accepted: 12/22/2010] [Indexed: 10/18/2022]
|
62
|
Roca F, Cailleux N, Benhamou Y, Scotte M, Lévesque H, Marie I. Un syndrome sclérodermiforme. Rev Med Interne 2011; 32:189-90. [DOI: 10.1016/j.revmed.2009.10.442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Accepted: 10/29/2009] [Indexed: 11/16/2022]
|
63
|
Miranda S, Verdet M, Hérona F, Vittecoq O, Lévesque H, Marie I. Erratum à la communication brève « Arthrites réactionnelles secondaires à la BCG-thérapie. Deux observations et revue de la littérature » [Rev. Med. Int. 31 (2010) 558–561]. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2010.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
64
|
Le Cam-Duchez V, Frétigny M, Cailleux N, Gandelin C, Lévesque H, Borg JY. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets. Thromb Res 2010; 126:e235-7. [DOI: 10.1016/j.thromres.2010.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2010] [Revised: 05/04/2010] [Accepted: 05/04/2010] [Indexed: 11/17/2022]
|
65
|
Belizna C, Henrion D, Beucher A, Lavigne C, Ghaali A, Lévesque H. Anti-Ku antibodies: Clinical, genetic and diagnostic insights. Autoimmun Rev 2010; 9:691-4. [DOI: 10.1016/j.autrev.2010.05.020] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2010] [Accepted: 05/26/2010] [Indexed: 10/19/2022]
|
66
|
Le Besnerais M, Benhamou Y, Girzyn N, Cailleux N, Lévesque H. Profil clinique, biologique et évolutif des ischémies digitales associées au cancer : association fortuite ou syndrome paranéoplasique ? Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
67
|
Chauffrey L, David N, Etienne M, Plissonnier D, Caron F, Pons JL, Lévesque H, Benhamou Y. Approche microbiologique des anévrismes infectieux de l’aorte au sein d’une cohorte de 21 patients : intérêt de la polymerase chain reaction (PCR). Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
68
|
Belizna C, Godin M, Joly P, Vittecoq O, Hamidou M, Faller B, Lévesque H. Étude prospective à cinq ans de 21 cas de cryofibrinogénémie essentielle. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
69
|
Miranda S, Janvresse A, Plissonnier D, Lévesque H, Marie I. Anévrismes infectieux de l’aorte. À propos d’une série de dix patients. Rev Med Interne 2010; 31:255-61. [DOI: 10.1016/j.revmed.2009.12.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2009] [Revised: 11/26/2009] [Accepted: 12/02/2009] [Indexed: 11/28/2022]
|
70
|
Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, Castellano MEM, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94:566-75. [PMID: 19336751 DOI: 10.3324/haematol.2008.001743] [Citation(s) in RCA: 296] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding and an isolated prolonged aPTT. AHA may, however, present without any bleeding symptoms, therefore an isolated prolonged aPTT should always be investigated further irrespective of the clinical findings. Control of acute bleeding is the first priority, and we recommend first-line therapy with bypassing agents such as recombinant activated FVII or activated prothrombin complex concentrate. Once the diagnosis has been achieved, immediate autoantibody eradication to reduce subsequent bleeding risk should be performed. We recommend initial treatment with corticosteroids or combination therapy with corticosteroids and cyclophosphamide and suggest second-line therapy with rituximab if first-line therapy fails or is contraindicated. In contrast to congenital hemophilia, no comparative studies exist to support treatment recommendations for patients with AHA, therefore treatment guidance must rely on the expertise and clinical experience of specialists in the field. The aim of this document is to provide a set of international practice guidelines based on our collective clinical experience in treating patients with AHA and contribute to improved care for this patient group.
Collapse
|
71
|
Benhamou Y, Le Cam-Duchez V, Schneller JM, Cailleux N, Magne JC, Soubrane JC, Borg JY, Lévesque H. Expérience d’un centre de suivi et de conseil des traitements anticoagulants oraux en médecine de ville : résultats à cinq ans. Rev Med Interne 2009; 30:567-72. [DOI: 10.1016/j.revmed.2009.02.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2008] [Revised: 01/28/2009] [Accepted: 02/08/2009] [Indexed: 11/16/2022]
|
72
|
Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009; 20:1459-1471. [PMID: 19525362 DOI: 10.1093/annonc/mdp052] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND In view of the lack of recommendations on central venous catheter (CVC)-associated thrombosis in cancer patients, we established guidelines according to the well-standardized Standards, Options and Recommendations methodology. MATERIAL AND METHODS A literature review (1990-2007) on CVC-associated thrombosis was carried out. The guidelines were developed on the basis of the corresponding levels of evidence derived from analysis of the 36 of 175 publications selected. They were then peer reviewed by 65 independent experts. RESULTS For the prevention of CVC-associated thrombosis, the distal tip of the CVC should be placed at the junction between the superior cava vein and right atrium; anticoagulants are not recommended. Treatment of CVC-associated thrombosis should be based on the prolonged use of low-molecular weight heparins. Maintenance of the catheter is justified if it is mandatory, functional, in the right position, and not infected, with a favorable clinical evolution under close monitoring; anticoagulant treatment should then be continued as long as the catheter is present. CONCLUSIONS Several rigorous studies do not support the use of anticoagulants for the prevention of CVC-associated thrombosis. Treatment of CVC-associated thrombosis relies on the same principles as those applied in the treatment of established thrombosis in cancer patients.
Collapse
|
73
|
Benhamou Y, Lachkar S, Cailleux N, Bauer F, Bernet J, Marie I, Lévesque H. Une myocardite à deux visages : maladie de Whipple ou sarcoïdose ? Rev Med Interne 2009; 30:430-3. [DOI: 10.1016/j.revmed.2008.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2008] [Revised: 11/04/2008] [Accepted: 12/01/2008] [Indexed: 10/21/2022]
|
74
|
Avenel G, Bernet J, Lahaxe L, Lévesque H, Marie I. [Subcutaneous calcifications and dysmorphic syndrome]. Rev Med Interne 2009; 31:238-40. [PMID: 19329231 DOI: 10.1016/j.revmed.2009.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2009] [Accepted: 02/02/2009] [Indexed: 10/21/2022]
|
75
|
Elias A, Debourdeau P, Renaudin JM, Desmurs-Clavel H, Mahé I, Elalamy I, Pavic M, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desruennes E, Douard MC, Grange C, Hocini H, Kriegel I, Le Gal G, Meyer G, Mismetti P, Quéré I, Scrobohaci ML, Lévesque H, Farge-Bancel D. Traitement curatif de la maladie thromboembolique veineuse et prise en charge des thromboses veineuses sur cathéter chez les patients atteints de cancer. Presse Med 2009; 38:220-30. [DOI: 10.1016/j.lpm.2008.11.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2008] [Accepted: 11/20/2008] [Indexed: 11/30/2022] Open
|